BioSpace News Archive

Pliant Therapeutics, Inc., a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, announced participation in the following April investor events.

Apollomics Inc. today announced poster presentations on vebreltinib (APL-101) at the 2024 American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, Calif.

OncoC4, Inc. announced the appointment of thoracic medical oncologist Heather A. Wakelee, MD, FASCO to the OncoC4 Scientific Advisory Board made up of distinguished scientists, industry experts, and key opinion leaders in oncology and immunotherapy.

Olink Holding AB announced the availability of an open access data library consisting of over 300,000 protein-disease risk associations, giving researchers a powerful new tool for revealing the biological mechanisms underlying 106 human diseases.

Vera Therapeutics, Inc. today announced two presentations of data from the Phase 2b ORIGIN clinical trial of atacicept for the treatment of IgA nephropathy (IgAN) will be made at the 61st European Renal Association Congress (ERA24), which is taking place May 23—26, 2024, both virtually and in Stockholm.

Eko Health announces FDA clearance for its Low EF detection AI. For the first time, U.S. healthcare providers can now detect Low EF, a key heart failure indicator, in 15 seconds using an Eko stethoscope during a routine physical examination.

Ratio Therapeutics Inc. announced the appointments of Bill Cupelo as the company’s Chief Business Officer and D. Scott Holbrook, MS, FSNMMI-TS to its Board of Directors.

Watchmaker Genomics, a provider of innovative solutions for molecular analysis, announced the launch of a high-purity RNase Inhibitor that is well-suited for a wide range of applications where maintaining RNA integrity is critical, including single-cell and single-nuclei sequencing, as well as pathogen detection.

Eureka Therapeutics, Inc. today announced the activation of UCSF Benioff Children’s Hospitals as the first California site to join the ARYA-2 clinical trial ( NCT04634357 ).

Avalo Therapeutics, Inc. announced the addition of multiple biotech leaders to its Board of Directors.